Adjuvant Systemic Therapy of Early Breast Cancer: A Case-Based
Panel Discussion
Target Audience
This activity has been designed to meet the educational needs
of oncologists, surgeons and radiation therapists involved
in the management of women with breast cancer.
Statement of Need/Program Overview
The options for systemic therapy of early breast cancer are
rapidly evolving, creating an educational imperative regarding
management strategies. This interactive symposium will
utilize a case-based approach to highlight integration
of emerging data on endocrine therapy and cytotoxic therapy
into the treatment of women with primary breast cancer.
Discussion will
include how evaluation of a patients’ risk of relapse,
results of clinical trials, risk/benefit ratios and patient
preference each contribute to the selection of appropriate
adjuvant therapy. Patterns of care data from community practice
will also be discussed.
Educational Objectives
Upon completion of this activity, participants should be
able to:
| • |
Counsel postmenopausal women with ER-positive, primary
breast cancer about the implications of the ATAC trial
data. |
| • |
Identify the optimal endocrine therapy approach for
managing premenopausal breast cancer patients. |
| • |
Evaluate the emerging data on dose-dense chemotherapy
and taxane-containing regimens and explain their relevance
to patients. |
| • |
Define the risk/benefit ratios for various endocrine
and cytotoxic therapies in individual patients and counsel
them regarding potential treatment options. |
Faculty & Affiliations
Michael Baum, MD, ChM, FRCS, FRCR
Emeritus Professor of Surgery and Visiting Professor of Medical
Humanities,
University College of London
Patrick I Borgen , MD
Chief, Breast Service, Department of Surgery,
Memorial Sloan-Kettering Cancer Center
George W Sledge, MD
Professor of Medicine,
Ballve-Lantero Professor of Oncology,
Indiana University Medical Center
Accreditation Statement
NL Communications Inc is accredited by the Accreditation
Council for Continuing Medical Education (ACCME) to provide
continuing medical education for physicians.
Credit Designation
NL Communications Inc designates this educational activity
for a maximum of 0.75 category 1 credit toward the AMA
Physician’s Recognition Award. Each physician should
claim only those credits that he/she actually spent on
the activity.
Commercial Support:
This program is supported by an education grant from AstraZeneca
Pharmaceuticals LP.
Faculty Disclosure Statement
As a provider accredited by the ACCME, it is the policy of
NL Communications Inc to require the disclosure of any
significant financial interest or any other relationship
the sponsor or faculty members have with the manufacturer(s)
of any commercial product(s) discussed in an educational
presentation. The presenting faculty reported the following:
Michael Baum, MD, ChM, FRCS, FRCR
Grants/Research Support: AstraZeneca Pharmaceuticals, LP
Consultant and Stockholder: Photo Electron Corporation
Patrick I Borgen , MD
No financial interests or affiliations to disclose.
George W Sledge, MD
Grants/Research Support/Consultant: Genentech Inc
Americans with Disabilities Act
 Event
staff will be glad to assist you with any special needs (i.e.
physical, dietary, etc.). Please contact Arai Penate prior
to the live event at 1-800-648-8654 or email: apenate@researchtopractice.net
|
